Search Results

You are looking at 31 - 40 of 62 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: All content x
Clear All
Free access

Margaux Foulfoin, Emmanuelle Graillot, Mustapha Adham, Pascal Rousset, Julien Forestier, Valérie Hervieu, Philip Robinson, Jean-Yves Scoazec, Catherine Lombard-Bohas, and Thomas Walter

systemic (somatostatin analogs (SSA), intravenous or per OS cytotoxic chemotherapy, targeted therapy such as everolimus and sunitinib and peptide receptor radionuclide therapy (PRRT)). We now have data from phase III studies investigating SSA ( Caplin et

Free access

Kosmas Daskalakis, Olov Norlén, Andreas Karakatsanis, Per Hellman, Rolf Larsson, Peter Nygren, and Peter Stålberg

and choice of therapy complicated ( Shi et al. 2015 ). With the exception of peptide receptor radionuclide therapy (PRRT) as a standard second line of treatment for metastatic SI-NETs, the mTOR inhibitor everolimus has emerged as the treatment of

Free access

Chiara Borga, Carlo Alberto Dal Pozzo, Elisabetta Trevellin, Francesca Bergamo, Sabina Murgioni, Anna Caterina Milanetto, Claudio Pasquali, Umberto Cillo, Giada Munari, Chiara Martini, Eugenio De Carlo, Vittorina Zagonel, Vincenza Guzzardo, Gianmaria Pennelli, Angelo Paolo Dei Tos, Roberto Vettor, and Matteo Fassan

for patients undergoing peptide receptor radionuclide therapy (PRRT) ( Werner et al. 2019 ). Moreover, recent evidences have pinpointed that primary and metastatic NETs are characterized by both intra-tumoral and inter-tumoral heterogeneous

Free access

Anela Blazevic, Martijn P A Starmans, Tessa Brabander, Roy S Dwarkasing, Renza A H van Gils, Johannes Hofland, Gaston J H Franssen, Richard A Feelders, Wiro J Niessen, Stefan Klein, and Wouter W de Herder

WL Khalifa M Ewang M Navalkissoor S Quigley AM Mandair D Caplin M Toumpanakis C 2019 Assessment of changes in mesenteric fibrosis (MF) after peptide receptor radionuclide therapy (PRRT) in midgut neuroendocrine tumours (NETs) . In 16th

Free access

Julie Refardt, Caroline M den Hoed, Janneke Langendonk, Wouter T Zandee, Ayoub Charehbili, Richard A Feelders, Wouter W de Herder, Tessa Brabander, and Johannes Hofland

progressive liver metastases 2 years after diagnosis in our center. Peptide receptor radionuclide therapy (PRRT) using 177 Lu-DOTATATE was initiated. In the meantime, however, the patient became disoriented in time and place, nauseous and developed a fine

Free access

Mohid S Khan and Martyn E Caplin

. 2004 ). There is limited experience with peptide receptor radionuclide therapy (PRRT) in the treatment of rare functioning tumours. However, its efficacy in other advanced pancreatic NETs with positive SSRS has been demonstrated ( Waldherr et al . 2002

Free access

Dorota Dworakowska and Ashley B Grossman

/CT scanning ( Xiao et al. 2015 ), suggesting that peptide receptor radionuclide therapy (PRRT) could be an alternative option for pituitary tumours resistant to TZM ( Goglia et al. 2008 ). However, very few patients are reported in the literature. A giant

Free access

Cristina Capatina, Georgia Ntali, Niki Karavitaki, and Ashley B Grossman

respective roles of chemotherapy and peptide receptor radionuclide therapy (PRRT) are yet to be clearly defined. Owing to the relatively mild natural history of HNPGLs, a long follow-up duration is needed before reaching a correct conclusion about the

Free access

Benjamin Easton White, Maralyn R Druce, Simona Grozinsky-Glasberg, Rajaventhan Srirajaskanthan, Eva Maria Gamper, Debra Gray, Ruben Mujica-Mota, and John K Ramage

population, and can be the most common symptom of all ( Fröjd et al. 2007 ). HRQoL measured in NEN clinical trials Treatments with the best efficacy in terms of PFS and symptom control in NEN are somatostatin analogues, peptide receptor radionuclide

Free access

Olga Lakiza, Julian Lutze, Alyx Vogle, Jelani Williams, Abde Abukdheir, Paul Miller, Chih-Yi ‘Andy’ Liao, Sean P Pitroda, Carlos Martinez, Andrea Olivas, Namrata Setia, Stephen J Kron, Ralph R Weichselbaum, and Xavier M Keutgen

radionuclide therapy (PRRT) ( Malcolm et al. 2019 ). The FDA-approved agent lutetium ( 177 Lu) octreotide is formed by binding the β-emitting isotope 177 Lu to DOTA linked to the cyclic peptide octreotate to target the somatostatin receptor 2 (SSTR2